期刊文献+

红斑狼疮需要引入目标治疗的理念 被引量:7

Tight control of SLE
原文传递
导出
摘要 鉴于心血管病、糖尿病等慢性疾病的治疗经验,目标治疗(treating to target)和严密控制(tight control)的概念已经向医学其他专科和其他疾病扩展.其中目标治疗是一种治疗理念,让临床的治疗有个明确方向和目标,即疾病一旦确诊,就应该朝着完全缓解的目标进行诱导治疗,即使无法达到完全缓解,也应该尽量控制在低度活动状态,才能够防止疾病对机体的危害,这就称为"目标治疗"[1].
作者 杨岫岩
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第11期723-724,共2页 National Medical Journal of China
  • 相关文献

参考文献4

  • 1Smolen JS,Aletaha D,Bijlsma JWJ,et al.Treating rheumatoid arthritis to target:recommendations of an international task force.Ann Rheum Dis,2010,69:631-937.
  • 2Bertsias GK,Salmon JE,Boumpas DT.Therapeutic opportunities in systemic lupus erythematosus:state of the art and prospects for the new decade.Ann Rheum Dis,2010,69:1603-1611.
  • 3Molino C,Fabbian F,Longhini C.Clinical approach to lupus nephritis:recent advances.Eur J Intern Med,2009,20:447-453.
  • 4杨岫岩,朱旬,梁柳琴,詹钟平,叶玉津.环磷酰胺治疗系统性红斑狼疮导致卵巢功能衰竭的相关因素分析[J].中华医学杂志,2005,85(14):960-962. 被引量:26

二级参考文献6

  • 1Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis : a meta-analysis of randomized controlled trials. Am J Kidney Dis,2004,43:197-208.
  • 2Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum,1982,25 : 1271-1277.
  • 3Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. a disease activity index for lupus patients. Arthritis Rheum, 1992,35:630-640.
  • 4Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythmatosus receiving cyclophosphamide therapy. Arthritis Rheum, 1998,41:831-837.
  • 5Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum, 1999,42 : 1274-1280.
  • 6杨岫岩.如何识别和控制临床研究中的混杂与偏倚[J].风湿病学杂志,2000,4(2):114-115. 被引量:19

共引文献25

同被引文献50

  • 1杨岫岩.以循证医学为基础的红斑狼疮个体化治疗[J].中华内科杂志,2004,43(8):562-563. 被引量:5
  • 2杨岫岩.糖皮质激素临床应用的似是而非[J].中国处方药,2005,4(9):24-27. 被引量:1
  • 3Bru,aner HI, Gladman DD, Ibadman, et al. Difference in disease features between childhood-onset and adult-onset systemie lu- pus erythematosus [ J ].Arthritis Rheum, 2008,58 (2) : 556-562.
  • 4Chrousos GP. The hypothalamic-pituitary-adrenal axis and im- mune-mediated inflammation [JI.N Engl J Med, 1995, 332 (20) : 1351- L362.
  • 5Buttgereit F, da Silva JA, Boers M, et al. Standardised nnmenela- ture for glucocorticoid dosages and glucocorticoid treatment regi- mens: current questions and tentative answers in rheumatnlo- gy [J].Ann Rheum Dis ,2002,61 8) :718-722.
  • 6Guidelines fur referrai and management of systemic lupus erythe- matosus in adults. American College of Rheumatology Ad HocCommittee on Systemic l,upus Erythemalosus C-uidelines [J].Ar- thritis Rheum, 1999,42(9) : 1785-1796.
  • 7Bootsma H. Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus [J].Lancet, 1995, 345 (8965) : 1595-1599.
  • 8Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995 [Jl.Arch Intern Med, 2000, 160(20) :3136-3140.
  • 9Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004 [J].J Rheumatol. 2009,36( 1 ) :63-67.
  • 10Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisit- ed [ J .Kidney lnt, 2004,65 (2) : 521-530.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部